Table 2. HR with 95% CI, for collection of T2DM-specific medications in the obese cohort.

	IFG i-ADA			IFG WHO			HbA1c prediabetes
	HR	95% CI	P value	HR	95% CI	P value	HR	95% CI	P value
Prediabetes	1.72	0.84–3.52	0.14	3.73	1.87–7.45	0.0002	3.12	1.50–6.52	0.002
Girls vs boys	1.99	1.04–3.81	0.04	2.10	1.09–4.04	0.03	1.95	0.95–4	0.07
Non-Scandinavian vs Scandinavian	0.84	0.42–1.68	0.62	1.14	0.56–2.32	0.72	1.05	0.47–2.36	0.90
Degree of obesity	1.79	1.03–3.10	0.04	1.93	1.16–3.21	0.01	2.11	1.14–3.88	0.02

Abbreviations: CI, confidence interval; HbA1c, hemoglobin A1c; HR, hazard ratio.

The models are adjusted for IFG (i-ADA in model 1 and WHO in model 2, n=1 620) and prediabetes according to Hba1c (model 3, n=1146), gender, ethnicity and degree of obesity. HR and 95% CI were calculated by the Cox's proportional hazards model. IFG i-ADA refers to 5.6–6.0 mmol l⁻¹, WHO refers to fasting glucose level of ⩾6.1 mmol l⁻¹, and prediabetic HbA1c refers to HbA1c 39–48 mmol l⁻¹ (ADA definition). Bold numbers indicate statistical significance.